RIPE-KG · Version 1.1.0 · Resource
ripekg:work/10.1016%2Fj.hsr.2025.100229
https://w3id.org/ripe/ripe-kg/work/10.1016%2Fj.hsr.2025.100229
| Subject | Predicate | Object |
|---|---|---|
ripekg:publication-details/RIPEAAAD6F9051C284833Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
ripe:concerns |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
ripekg:registry-evidence/RIPEAAAD6F9051C284833 |
ripe:concerns |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
ripekg:research-integrity-assessment/RIPEAAAD6F9051C284833 |
ripe:assesses |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
ripekg:study-design-evidence/RIPEAAAD6F9051C284833 |
ripe:concerns |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
prism:doi |
10.1016/j.hsr.2025.100229 |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
dcterms:creator |
ripekg:author/RIPEAU6558EA2E6021AD0FMd Hossen |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
dcterms:creator |
ripekg:author/RIPEAUABE113C0581EF4BDAfroza Rahman |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
dcterms:creator |
ripekg:author/RIPEAUD2E018A91E746038Sadia Bari |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
dcterms:creator |
ripekg:author/RIPEAUE0650447BA41F174K Saif-Ur-Rahman |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
dcterms:title |
Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
http://purl.org/spar/cito/cites |
ripekg:work/10.1186%2Fs13643-016-0384-4Rayyan-A web and mobile app for systematic reviews |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW0B60C14BD411F84BEffects of dapagliflozin on blood pressure variability in patients with prediabetes and prehypertension without pharmacological treatment: a randomized trial |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW156240D6A68302ECThe metabolic syndrome |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW2D80690D7E9B332CPrioritization and sequential exclusion of articles in systematic reviews |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW36B4B0D096949384Effect of dapagliflozin administration on metabolic syndrome, insulin sensitivity, and insulin secretion |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW38A8D013F33A2A12Effect of Dapagliflozin on insulin secretion and insulin sensitivity in patients with prediabetes |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW5132E0C30B1C12FBAmbulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW5BF403E898F86DD2Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW63884E1568C87370Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW6F2DA245AB265787Dapagliflozin once-daily and exenatide once-weekly dual therapy: a 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW6F66C0B6AD1BDC42Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic β -cell function and reduction of insulin resistance |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW772620E10F329A51SGLT-2 inhibitors in obesity and its associated cardiometabolic disorders: where do we stand? |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW83EE989360E14440Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW85F70CC5130BE705The PRISMA 2020 statement: an updated guideline for reporting systematic reviews |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW85F70CC5130BE705The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW956632C4EEEDF59CThe effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW99A435E4B32A67D5Canagliflozin: effects in overweight and obese subjects without diabetes mellitus |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEWA69CF3C2785BBA4EEmerging Roles of SGLT2 Inhibitors in Obesity and Insulin Resistance: Focus on fat Browning and Macrophage Polarization |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEWAACE095368E66D9BSodium-glucose Cotransporter-2 inhibitors in non-diabetic adults with overweight or obesity: a systematic review and meta-analysis |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEWD083865068A06986Metabolic syndrome-a new world-wide definition. a consensus statement from the international diabetes federation |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
rdf:type |
node1 |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
rdf:type |
http://purl.org/spar/fabio/Work |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
rdf:type |
rdfs:Resource |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
rdf:type |
owl:Thing |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
rdf:type |
prov:Entity |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
rdf:type |
ripe:WorkWork |
ripekg:work/10.1016%2Fj.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
owl:sameAs |
https://semopenalex.org/work/W4410090977 |